表紙
市場調査レポート

米国のアルツハイマー病用造影剤の機会

US Opportunities for Alzheimer's Imaging Agents 2014

発行 Decision Resources Group - Medtech Solutions 商品コード 292013
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
米国のアルツハイマー病用造影剤の機会 US Opportunities for Alzheimer's Imaging Agents 2014
出版日: 2013年12月18日 ページ情報: 英文
概要

初のアルツハイマー病用造影剤Amyvidは2012年4月に米国に上市されました。同市場の規模は2013年現在は300万米ドルに満たないものですが、2022年にかけ急速に拡大するものとみられています。

当レポートでは、米国における臨床環境の概説とともに、アルツハイマー病用造影剤および核医学システム市場の概要と競合動向、将来的展望をまとめ、概略下記の構成で取り上げております。

エグゼクティブサマリー

第1章 国の概要

  • 米国
    • 人口統計と経済
    • 医療制度

第2章 臨床環境

  • 疾患概要
  • 処置概要
    • ベータアミロイド造影処置
  • 競合する診断方法
    • 神経心理学検査
    • 試験所検査
    • 構造造影処置
    • 機能造影処置
    • 脳脊髄液サンプリング
    • ピッツバーグ化合物B造影処置
  • ガイドラインと診断パターン
    • 診断および紹介パターン

第3章 製品

  • アルツハイマー病用造影剤
  • 核医学システム

第4章 治験

第5章 アルツハイマー病用造影剤市場

  • 市場概要
  • 詳細な市場分析
    • 収益別
    • モダリティ別
    • 設備別
  • 競合概要
  • 詳細な競合環境
  • 近年のイベント
  • 最も有望な新興製品

第6章 核医学システム市場

  • 市場概要
  • 詳細な市場分析

付録

図表

目次
Product Code: RPUS50AZ13

The first Alzheimer's imaging agent, Amyvid, became available in the US in April 2012 and, though the market for these products was valued at less than $3 million in 2013, increased coverage and the launch of the first DMT for AD will help the market to experience rapid expansion through 2022.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for Alzheimer's imaging agents in the US across a 10-year period.

Millennium Research Group has up-to-date reports on a wide range of medical device markets worldwide.

Questions Answered in This Report:

* In April 2012, Amyvid became the first Alzheimer's imaging agent available on the US market. Despite the product's ability to aid physicians in arriving at an earlier diagnosis for AD, very few commercial procedures were performed in 2012 and 2013.

What factors have limited procedure volumes following the product's introduction to the market?

In which facilities are the majority of these procedures currently being performed?

What systems are currently being used to perform these procedures, and how will this change over the forecast period?

* While there was only one product on the market in 2013, a number of competitors, including GE Healthcare, Piramal Enterprises, and Navidea Biopharmaceuticals, are all expected to launch products into the market.

When is each competitor expected to launch its Alzheimer's imaging agent on the market?

How will price competition affect the ASP of Alzheimer's imaging agents through 2022?

What strategies can competitors employ to drive market share gains going forward?

* Going forward, a number of key events will significantly impact the beta-amyloid imaging market. In addition to the commencement of CED trials, the first DMT for AD will reach the market in 2018.

What impact will the improved access of beta-amyloid imaging procedures through CED trials have on the market size?

How will the launch of the first DMT affect referrals for beta-amyloid imaging scans?

Scope:

Geographies Covered: US

Market Forecast Features: Based on primary research with industry professionals, Millennium Research Group uses its proprietary forecasting model to provide an in-depth examination of current and future trends in procedure volumes, unit sales, ASPs, installed base, and market values over a 10-year period (2012-2022).

Competitive Analysis: Millennium Research Group provides a detailed analysis of the competitive landscape and market shares for leading competitors.

Authors:

  • Jeremy Seath
  • Felix Lam, M.Sc.

Contributors

  • April Chan
  • Karen Gierszewski
  • Samuli Heilala, M.Sc.
  • Nancy Huynh
  • Alice-Louise Madden, M.Sci

Table of Contents

TABLE OF CONTENTS

LIST OF FIGURES AND TABLES

EXECUTIVE SUMMARY

1 COUNTRY OVERVIEWS

  • 1.1 US
    • 1.1.1 Demographics and Economy
    • 1.1.2 Health Care System
    • 1.1.3 Regulatory Environment

2 CLINICAL LANDSCAPE

  • 2.1 Disease Description
  • 2.2 Procedure Descriptions
    • 2.2.1 Beta-Amyloid Imaging Procedures
  • 2.3 Competing Diagnostic Methods
    • 2.3.1 Neuropsychological Testing
    • 2.3.2 Laboratory Testing
    • 2.3.3 Structural Imaging Procedures
    • 2.3.4 Functional Imaging Procedures
    • 2.3.5 Cerebrospinal Fluid Sampling
    • 2.3.6 Pittsburgh Compound B Imaging Procedures
  • 2.4 Guidelines and Diagnosis Patterns
    • 2.4.1 Diagnostic and Referral Patterns

3 PRODUCTS

  • 3.1 Alzheimer's Imaging Agents
  • 3.2 Nuclear Medicine Systems

4 CLINICAL TRIALS

5 ALZHEIMER'S IMAGING AGENT MARKET

  • 5.1 Market Snapshot
  • 5.2 Detailed Market Analysis
    • 5.2.1 By Revenue Type (Procedures Only)
    • 5.2.2 By Modality (Procedures Only)
    • 5.2.3 By Facility Type (Procedures Only)
  • 5.3 Competitive Snapshot
  • 5.4 Detailed Competitive Landscape
  • 5.5 Recent Events
  • 5.6 Most Promising Emerging Products

6 NUCLEAR MEDICINE SYSTEM MARKET

  • 6.1 Market Snapshot
  • 6.2 Detailed Market Analysis

APPENDIX: METHODOLOGY

APPENDIX: ACRONYMS AND INITIALISMS

APPENDIX: BIBLIOGRAPHY

LIST OF FIGURES AND TABLES

TABLE OF CONTENTS

LIST OF FIGURES AND TABLES

EXECUTIVE SUMMARY

  • Table 1: Alzheimer's Imaging Agent Market Landscape, US (USD), 2013 and 2022
  • Figure 1: Beta-Amyloid Imaging Procedures, by Facility Type, as a % of Total, US, 2013 and 2022
  • Table 2: Companies Mentioned
  • Table 3: Factors Impacting the Alzheimer's Imaging Agent Market, US
  • Table 4: Recent Events in the Alzheimer's Imaging Agent Market, US, 2013
  • Table 5: Expected Key Events in the Alzheimer's Imaging Agent Market, US
  • Table 6: Alzheimer's Imaging Agent Procedures Covered, US
  • Table 7: Alzheimer's Imaging Agents and Nuclear Medicine Systems Covered, US

1 COUNTRY OVERVIEWS

  • Table 8: Key Health and Economic Indicators, US

2 CLINICAL LANDSCAPE

3 PRODUCTS

4 CLINICAL TRIALS

  • Table 9: Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain
  • Table 10: Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult Subjects
  • Table 11: Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral Β- amyloid Compared to Histopathology
  • Table 12: A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology
  • Table 13: Amyloid-Β Imaging with Pittsburgh Compound B and Florbetapir
  • Table 14: Bridging Study of C11 PiB and F18 Flutemetamol Brain PET
  • Table 15: The Feasibility of Florbetapir Quantitation
  • Table 16: Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline

5 ALZHEIMER'S IMAGING AGENT MARKET

  • Figure 2: Alzheimer's Imaging Agent Market, US (USD), 2012-2022
  • Table 17: Factors Impacting the Alzheimer's Imaging Agent Market, US
  • Table 18: Prevalent Cases of Alzheimer's Disease, by Population, US, 2012, 2017, and 2022
  • Table 19: Alzheimer's Imaging Agent Market, US (USD), 2012-2022
  • Table 20: Other Imaging Procedures, by Procedure Type, US, 2012-2022
  • Table 21: Beta-Amyloid Imaging Procedures, by Revenue Type, US, 2012-2022
  • Table 22: Beta-Amyloid Imaging Procedures, by Modality, US, 2012-2022
  • Table 23: Beta-Amyloid Imaging Procedures, by Facility Type, US, 2012-2022
  • Table 24: Recent Events in the Alzheimer's Imaging Agent Market, US
  • Table 25: Emerging Products in Development for the Alzheimer's Imaging Agent Market, US

6 NUCLEAR MEDICINE SYSTEM MARKET

  • Figure 3: Nuclear Medicine System Market, by Modality, US (USD), 2012-2022
  • Table 26: Nuclear Medicine System Market, by Modality, US (USD), 2012-2022
  • Table 27: Nuclear Medicine System Market Growth, by Modality, US, 2013-2022
  • Table 28: Nuclear Medicine System Installed Base, by Modality, US, 2012-2022

APPENDIX: METHODOLOGY

APPENDIX: ACRONYMS AND INITIALISMS

  • Table 29: Acronyms and Initialisms

APPENDIX: BIBLIOGRAPHY

Back to Top